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Abstract 
Background: SWI/SNF is a large heterogeneous multi-subunit chromatin remodeling complex. It consists of multiple 
sets of mutually exclusive components. Understanding how loss of one sibling of a mutually exclusive pair affects the 
occupancy and function of the remaining complex is needed to understand how mutations in a particular subu-
nit might affect tumor formation. Recently, we showed that the members of the ARID family of SWI/SNF subunits 
(ARID1A, ARID1B and ARID2) had complex transcriptional relationships including both antagonism and cooperativity. 
However, it remains unknown how loss of the catalytic subunit(s) affects the binding and genome-wide occupancy of 
the remainder complex and how changes in occupancy affect transcriptional output.
Results: We addressed this gap by depleting BRG1 and BRM, the two ATPase subunits in SWI/SNF, and characterizing 
the changes to chromatin occupancy of the remaining subunit and related this to transcription changes induced by 
loss of the ATPase subunits. We show that depletion of one subunit frequently leads to loss of the remaining subunit. 
This could cause either positive or negative changes in gene expression. At a subset of sites, the sibling subunit is 
either retained or gained. Additionally, we show genome-wide that BRG1 and BRM have both cooperative and antag-
onistic interactions with respect to transcription. Importantly, at genes where BRG1 and BRM antagonize one another 
we observe a nearly complete rescue of gene expression changes in the combined BRG/BRM double knockdown.
Conclusion: This series of experiments demonstrate that mutually exclusive SWI/SNF complexes have heterogene-
ous functional relationships and highlight the importance of considering the role of the remaining SWI/SNF com-
plexes following loss or depletion of a single subunit.
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Background
The SWI/SNF complex contains 12–15 subunits [1–3], 
which are combinatorially assembled to create as many 
as several thousand biochemically distinct complexes. In 
development, changes to composition of SWI/SNF can 
drive developmental progression [4, 5]. In cancer, SWI/
SNF is among the most commonly found mutations, with 
mutations observed in as many as 20% of tumors [6, 7]. 
However, these mutations are not equally spread across 
the subunits. Mutations in the ARID family members 
(ARID1A, ARID1B and ARID2) and the ATPase subunits 
(BRG1 and BRM) are more prevalent than in the other 
subunits [6, 7]. Additionally, in some cancers multiple 
subunits are mutated. This is the case in hepatocellular 
carcinoma where mutations have been identified in all 
three ARID subunits [8–10]. In other cancers, mutations 
are highly specific, such as BRG1 mutations in small cell 
carcinoma of the ovary hypercalcemic type (SCCOHT) 
[11] and SNF5 mutations in malignant rhabdoid tumors 
[12], and ARID1A in ovarian clear cell carcinoma [13–
15]. The varied relationship between mutations in a par-
ticular SWI/SNF subunit and the generation of tumors 
represents a challenge for determining how the SWI/SNF 
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complex affects transcription and other cellular processes 
during oncogenesis.
We previously used the three ARID subunits as a model 
to understand how depletion of a single ARID family 
member affected transcription in HepG2, a well-studied 
liver cancer line [16]. We showed that the ARID family 
members had a complex relationship that included both 
cooperative and antagonistic control of genes. Surpris-
ingly, ARID1B and ARID2 had a highly cooperative effect 
on gene expression, while ARID1A showed both coop-
erative and antagonistic effects. Additionally, we showed 
that all three ARIDs bound a highly overlapping set of 
regions, but that differences in the cofactors at subsets 
of regions might reflect functionally different complexes. 
However, in that study we did not determine how loss of 
one of these subunits affected the genomic occupancy of 
the remaining subunits. It has been shown that SWI/SNF 
targeting can be affected by a variety of other chromatin 
regulating families [17, 18], including direct competi-
tion with PRC1 [19]. Additionally, in synovial sarcoma, 
the inclusion of an oncogenic fusion protein evicts a core 
subunit from the complex and leads to retargeting of the 
remainder complex [20]. However, currently no study has 
investigated the effect of removing one of the mutually 
exclusive subunits on the chromatin occupancy of its sib-
ling subunit. Loss of a single member of the complex is 
the most frequent type of SWI/SNF alteration in cancer, 
therefore understanding how this affects the remaining 
complexes function in mechanistic detail is critical.
In this study, we examine how loss of one subunit of a 
mutually exclusive pair affected the localization of its sib-
ling subunit. We conducted an analysis on the two mutu-
ally exclusive ATPAse subunits, BRG1 and BRM (also 
known as SMARCA4 and SMARCA2, respectively). The 
functional interactions between BRG1 and BRM were 
not uniform. The predominant effect in HepG2 cells of 
loss of either BRG1 or BRM is the loss of the remaining 
subunit (~ 50–70% of sites). This occurs at genes that are 
both activated and repressed by BRG1 and BRM. In a 
subset of cases, the sibling subunit is selectively retained 
or gained upon loss of the other subunit from chroma-
tin (~ 30–50% of sites). A predominant loss of SWI/SNF 
occupancy upon loss of one subunit has been observed in 
other cell types [21]. Similar to our findings on ARID1A 
and either ARID1B or ARID2, BRG1 and BRM often 
antagonize one another in transcriptional control. In 
cases of antagonism, a combined knockdown of BRG1 
and BRM rescued the expression changes globally. These 
results demonstrate that complex functional interac-
tions exist between mutually exclusive SWI/SNF com-
plexes and highlight the importance of characterizing 
the effects on the complexes that remain in SWI-/SNF-
mutated tumors. We present a model to understand the 
heterogeneity of regulation, where interactions between 
distinct SWI/SNF complexes act as a first layer of tran-
scriptional control. Loss of one form of the complex 
unmasks a second layer of transcriptional control that 
can be either activating or repressive depending on the 
specific chromatin regulators recruited to a site.
Results
BRG1 and BRM depletion leads to distinct morphology 
changes in HepG2 cells
We investigated the effect of depleting one of a mutu-
ally exclusive pair of sibling SWI/SNF subunits on tran-
scription and on SWI/SNF occupancy in HepG2 cells 
using a series of ChIP-seq and RNA-seq experiments. 
We selected HepG2 because they are a common and 
well-studied liver cancer cell line and extensive ENCODE 
ChIP-seq and chromatin state data are available for these 
cells. Using shRNA targeting either BRG1 or BRM, we 
depleted HepG2 cells of these proteins and performed 
RNA-seq or ChIP-seq in these models. Knockdown of 
BRG1 using two shRNAs in HepG2 cells causes cells to 
become elongated or spindly (Fig.  1a–c). Knockdown 
of BRM using two shRNAs led to a different morphol-
ogy with cells appearing more flattened and lacking the 
tightly packed morphology of a non-silencing control 
(Fig.  1b–d). This suggested that BRG1 and BRM have 
distinct effects on HepG2 cells. We selected the stronger 
shRNA (BRG1 shRNA#2 and BRM shRNA#1) to perform 
further RNA-seq and ChIP-seq experiments.
Sibling subunits control distinct and overlapping 
transcriptional programs
We first compared the effect of knockdown of BRG1 to 
BRM by RNA-seq. ShRNA targeting BRG1, BRM, or tar-
geting both BRG1 and BRM was used to deplete HepG2 
of the mutually exclusive subunits and subjected to RNA-
seq. The shRNAs selectively targeted the appropriate 
subunit at the protein (Fig. 2a) and RNA level (Fig. 2b). 
At the RNA level, most SWI/SNF subunits are unaffected 
by knockdown of either BRG1 or BRM or knockdown of 
both combined (Additional file  1). Consistent with our 
observations in Fig. 1, shBRG1 and shBRM induced dis-
tinct changes to cell morphology (Fig.  2c). The double 
knockdown was a mixture of the two, although with con-
siderably less severe morphology changes than shBRG1 
alone.
We focused our analysis on genes that are direct tar-
gets of BRG1/BRM by analyzing genes associated with 
a ChIP-seq peak of BRG1 or BRM. To that end, we per-
formed ChIP-seq in these models as well and discuss the 
analysis of these data below (Fig.  3). For each peak, we 
assigned the nearest gene as its direct target. We detected 
many direct target genes that changed following loss of 
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BRG1 (3103), BRM (1188) or the double knockdown 
(3046) (Additional files 2, 3, 4). We used GSEA analysis 
to identify categories of genes that are affected by BRG1 
or BRM loss [22, 23]. In the BRG1 knockdown, we found 
a strong decrease in genes associated with liver identity 
and an upregulation of genes associated with an epithe-
lial to mesenchymal transition (Fig. 2d, Additional file 5). 
Knockdown of BRM led to distinct changes in gene cate-
gories including an upregulation of genes involved in adi-
pogenesis and fatty acid metabolism (Fig. 2e, Additional 
file 6). In total, we found that 3860 genes were regulated 
by either BRG1 or BRM, and 431 genes were regulated 
by both BRG1 and BRM. Additionally, we observed 
1023 directly regulated genes that were only affected in 
the double knockdown which may signify a redundant 
role for BRG1 and BRM in the regulation of these genes 
(19% of affected genes). In total, these data show that 
5314 were dysregulated by loss of at least one SWI/SNF 
ATPase subunit of the total 35010 genes with measure-
able transcription in our assay (15%).
Plotting the fold changes of shBRG1 against shBRM 
revealed that direct targets of BRG1 and BRM were both 
concordantly and discordantly regulated (Fig. 2f ), similar 
to our previous observations for ARID1A and ARID1B 
[16]. We assigned each gene to a particular class based 
on the observed expression changes following BRG1 and 
BRM loss. This yielded four categories: Both Up (n = 89), 
Both Down (n = 111), BRG1 Up BRM Down (n = 115) 
and BRG1 Down BRM Up (n = 116) (Fig. 2f, Additional 
file  7). We then analyzed expression at each of these 
classes following knockdown by the single or double 
shRNA. At sites that were regulated concordantly (Both 
Up or Both Down), the double knockdown exaggerated 
the effect slightly, driving expression slightly higher or 
lower than the single knockdown (Fig. 2g). At genes that 
were regulated discordantly, however, there was a robust 
effect of the double knockdown. In both cases where 
BRG1 loss upregulated a gene or downregulated a gene 
and BRM had the opposite effect, the double knockdown 
strongly blunted these changes returning expression 
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Fig. 1 Depletion of BRG1 in HepG2. a Morphology changes in HepG2 following treatment with two shRNAs targeting BRG1. b Morphology 
changes in HepG2 following treatment with two shRNAs targeting BRM. c Western blot of BRG1 following knockdown. d Western blot following 
BRM knockdown
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nearly to baseline (Fig.  2g). Therefore, at genes where 
BRG1 and BRM function regulates genes discordantly, 
we found they functionally antagonize one another. We 
previously observed a similar effect between ARID1A 
and either ARID1B or ARID2, but at only small number 
of genes tested individually. These data confirm our pre-
vious result and extend it to a new set of mutually exclu-
sive subunits genome-wide [16]. These data demonstrate 
that BRG1 and BRM can have both cooperative and 
antagonistic effects on gene expression.
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Fig. 2 RNA-seq in BRG1, BRM and combined knockdown. a Western blot of HepG2 cells treated with shRNA targeting BRG1, BRM or both com-
bined. b Log2 normalized read counts of RNA-seq data HepG2 treated with BRG1, BRM or both combined shRNA. c Morphology changes of shRNA 
conditions. d GSEA analysis of expression changes following shRNA targeting BRG1 and BRM. f Fold changes of genes significantly differentially 
expressed and bound by BRG1 and BRM. g Effect on genes in f following treatment with the individual and double knockdown shRNA
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BRG1 and BRM concordant and discordant sites are 
associated with distinct transcriptional programs
We performed gene ontology analysis using categories 
from the Molecular Signature Database (MSigDB) using 
the C2 (genetic and chemical perturbations) and the H 
(Hallmark) series of annotations ([22, 23], Additional 
file  7). Genes associated with concordant BRG1/BRM 
regulation that both increase following BRG1 or BRM 
loss were associated with TNF-alpha signaling through 
NFKB. Genes associated with concordant BRG1/BRM 
regulation that both decrease following BRG1/BRM 
loss were associated with genes upregulated in hepato-
blastoma (CAIRO_HEPATOBLASTOMA_UP) or liver 
cancer with CTNNB1 mutations (CHIANG_LIVER_
CANCER_SUBCLASS_UP). These categories are con-
sistent with the cellular origin of HepG2 and might 
suggest expression of BRG1 and BRM was important 
for transformation of this tumor. In cases where BRG1/
BRM regulated a gene discordantly, these genes were 
associated with several ontologies that discriminated 
between two subsets of cancer types (CHARAFE_
BREAST_CANCER_LUMINAL_VS_BASAL_DN and 
CHARAFE_BREAST_CANCER_LUMINAL_VS_MES-
ENCHYMAL_DN). Finally, genes specifically altered 
only when both BRG1 and BRM are depleted (redun-
dant genes) were enriched for ontologies associated 
with general transcription, cell signaling and apoptosis 
(REACTOME_GENERIC_TRANSCRIPTION_PATH-
WAY, REACTOME_CELL_CELL_COMMUNICATION, 
PID_PIK3CIPATHWAY, CONCANNON_APOPTO-
SIS_BY_EPOXOMICIN_UP—see Additional file  8 for 
full results).
BRG1 and BRM occupy similar genomic loci
We next wanted to determine how the localization of 
BRG1 and BRM relates to one another; therefore, we 
performed a series of ChIP-seq experiments in shNS, 
shBRG1 and shBRM cells. In shNS cells there was a 
high degree of overlap between BRG1 and BRM. Nearly 
all BRM peaks overlapped a BRG1 peak (Fig.  3a). The 
high degree of similarity was evident at specific sites as 
well as genome-wide (Fig.  3b, c). The lack of complete 
overlap between BRG1 and BRM is likely due to differ-
ences in antibody efficiency given the high correlation 
in signal. BRG1/BRM occupancy was mostly associ-
ated with active regulatory regions of the genome based 
on ChromHMM annotations including promoters and 
strong enhancers (Fig.  3d, Additional files  9, 10) [24]. 
The high degree of ChIP-seq overlap was not due to the 
antibodies precipitating both ATPase subunits together. 
Co-immunoprecipitation experiments show that BRG1 
and BRM immunoprecipitated other SWI/SNF members 
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Fig. 3 BRG1 and BRM occupy common genomic regions. a Overlap between BRG1 and BRM ChIP-seq peaks. b Example of BRG1 and BRM occu-
pancy. c Scatterplot of BRG1 and BRM signal at union set of BRG1 and BRM peaks. c Venn diagram depicting overlap between BRG1 and BRM sites. 
d ChromHMM features associated with BRG1 and BRM peaks. e BRG1 and BRM ChIP-seq signal centered on TSS stratified by expression level of gene 
into low, medium and high expression. f Co-immunoprecipitation of BRG1 and BRM followed by Western blot of SWI/SNF subunits. Asterisks denote 
IgG heavy chain. g Glycerol ultracentrifugation of SWI/SNF subunits
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(ARID1A, BAF60A, BAF53A, BAF47) while not immu-
noprecipitating each other (Fig. 3f ). The IP of BRM was 
weaker than BRG1 due either to lower protein abun-
dance or IP efficiency. Glycerol gradient ultracentrifuga-
tion analysis shows that both BRG1 and BRM are found 
in later fractions, indicating that both subunits assemble 
into similar sized SWI/SNF complexes (Fig. 3g). HDAC1 
is not a SWI/SNF complex member and is not immuno-
precipitated by either antibody and is found in a distinct 
set of fractions following ultracentrifugation on a glycerol 
gradient (Fig. 3f, g).
Depletion of BRG or BRM leads to loss of occupancy of the 
remaining sibling complex
We next wished to determine how localization one sib-
ling subunit is affected following loss of the other sib-
ling. To address this, we performed ChIP-seq on BRM 
and BRG1 following knockdown of either BRG1 or BRM 
(Additional files 9, 10). Knockdown of BRG1 led to a 
decrease genome-wide of BRG1 signal to approximately 
half of shNS levels (Fig.  4a, b). Depletion of BRM led 
to a very robust decrease to near background levels of 
BRM occupancy (Fig.  4a, c). Consistent with the over-
all decrease in signal, we observed a reduction in the 
number BRG1 peaks following BRG1 knockdown from 
(44298 in shNS to 19032 in shBRG1, Fig. 4e, Additional 
file 9). In shBRM-treated HepG2, cells we identified only 
90 peaks compared to 16652 in shNS cells, suggesting 
that BRM is nearly completely depleted in these cells 
(Fig.  4f, Additional file  10). The difference in efficiency 
could reflect difference in shRNA activity, differences in 
normal levels of these proteins or the differences in the 
ability of cells to tolerate a complete loss of BRG com-
pared to BRM.
We then compared the effect of shBRG1 and shBRM 
to the occupancy of the opposite ATPase. That is, how 
does loss of BRM affect BRG1 occupancy genome-wide 
(Fig. 5a–d). We focused our analysis on the regions of the 
genome that lost occupancy for the first subunit because 
these are the most likely places to observe a robust 
change in the sibling subunit. At the 25913 regions that 
loss a BRG1 peak in shBRG1-treated cells, we observed 
a moderate decrease in both BRG1 and BRM signals in 
shBRG1 (Fig. 5a, b). At these sites, shBRM treatment led 
not only to the decrease in BRM occupancy, but also led 
to a strong decrease in BRG1 occupancy. We performed 
the reverse analysis, focusing on the 16564 lost BRM 
peaks in shBRM-treated cells. These sites also lost occu-
pancy of the sibling subunit. For example, BRG1 ChIP-
seq signal in shBRM-treated cells decrease relative to 
shNS (Fig. 5c, d). Together, these data suggest that BRG1 
and BRM reinforce one another’s occupancy despite not 
physically interacting with one another. This was not due 
to off-target shRNA effects or cross-reactivity between 
our antibodies (Figs. 2a, b, 3e). Despite mostly a decrease 
in signal, slightly less than half of sites overlapped a 
region that remained called as a peak or was a new peak. 
We classify these sites as retained.
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Fig. 4 ChIP-seq on BRG1 and BRM in cells depleted of these subunits. a Heatmap showing effect of BRG1 and BRM depletion on BRG1 and BRM 
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Loss of BRG1/BRM occupancy is associated with both 
activating and repressing activities
To determine how loss of or retention of the sibling subu-
nit regulated transcription, we grouped the genes associ-
ated with peaks that lose a subunit into four categories 
(Fig. 5e, f ). Group 1 genes are genes that lose BRG1 and 
lose a BRM peak. Group 2 genes are those that lose BRG1 
and gain or retain a BRM peak. Group 3 genes are those 
that lose BRM and lose BRG1, and Group 4 genes are 
those that lose BRM and gain or retain BRG1. We chose 
to classify gained/retained together because we could 
not be sure these reflected actual new peaks or quantita-
tive differences in ChIP occupancy that increased above 
the threshold necessary for a peak to be called. Using 
this classification scheme, we analyzed the expression 
changes from our RNA-seq experiment and performed 
GSEA analysis. Many of the genes associated with each of 
the categories changed expression. There was a modest, 
but significant difference at these categories in response 
to different shRNA conditions (Fig. 5g, h). For example, in 
Group 1 genes, shBRG1 caused genes to decrease expres-
sion, while shBRM caused genes to increase expression 
(Wilcoxon test, p value  <  0.05 against hypothesis of no 
fold change). This effect was consistent with our observa-
tion that BRG1 and BRM could function antagonistically. 
Finally, we looked broadly at whether loss of BRG1/BRM 
peaks affected transcription of the associated genes with-
out specifically asking about the direction or magnitude 
of change. Compared to genes that were not associated 
with a BRG1 or BRM peak in one of the above categories, 
genes in all four groups were more significantly more 
likely to affect gene expression (χ2 test, p value < 0.05).
We explored the functional annotations associated 
with these and again found that specific categories of 
genes were affected differentially by BRG1 and BRM 
(Additional file  11). Among genes where BRG1 is lost, 
but BRM is gained or retained, we found enrichment for 
genes involved in TNF-alpha signaling through NFKB 
(Fig.  6a). Notably, this enrichment was affected oppos-
ingly by BRG1 and BRM and is consistent with occu-
pancy changes where BRG1 is lost and BRM remains. 
In cells treated with shBRG1, expression of this gene set 
increased, showing that BRG1 is a negative regulator of 
this pathways transcription, while BRM is a positive reg-
ulator. A second example was found in Group 4. Here we 
found that BRG1 negatively regulated fatty acid metabo-
lism, while BRM was the positive regulator. These results 
suggest that BRG1 and BRM act as site-specific regula-
tors of transcription, and the direction of that regulation 
cannot be explained simply by their occupancy.
Altered SWI/SNF transcriptional controls is associated 
with distinct cofactors
Our results demonstrate that BRG1 and BRM have 
numerous functional interactions in HepG2 cells. The 
effect on transcription of these interactions does not 
depend simply on the occupancy of BRG1 and BRM, but 
through some site-specific regulatory control. One pos-
sibility is that BRG and BRM may directly or indirectly 
interact with other chromatin and transcriptional regu-
lators to control the output at a specific site. To address 
this hypothesis, we made use of the extensive data avail-
able from the ENCODE project for HepG2. Using these 
data, we compared the level of ChIP-seq signal for each 
factor available in ENCODE at regions that lose both sib-
ling subunits to those that lose one sibling while retaining 
or gaining the other sibling. We did not find any factors 
for which there was complete absence in one group and 
presence in another. However, we found several examples 
of factors with quantitative differences in levels (Fig. 7a–
c). We found a strong enrichment for EZH2 at regions 
that lose both BRG1 and BRM (Fig.  7a). Conversely, 
we found that HNF4A and FOXA1 were more strongly 
enriched at regions that lost BRM, but gain or retain 
BRG1 (Fig.  7b, c). These data suggest that functional 
interactions between different SWI/SNF complexes and 
other chromatin regulating complexes may play a role in 
the ultimate outcome of SWI/SNF disruption.
Discussion
In this study, we aimed to understand how occupancy 
by two mutually exclusive SWI/SNF complexes, dis-
tinguished here by the ATPase subunit, changed when 
one form of the complex was depleted. Our goal was to 
tie these changes in occupancy to changes in transcrip-
tion and identify factors that contribute to the choice 
of mechanism. We found that transcriptional control 
and occupancy are complex and include a myriad of 
mechanisms that are controlled in site-specific ways 
(Fig.  8). Careful dissection of the factors that associate 
(See figure on previous page.) 
Fig. 5 Occupancy and transcriptional changes associated with BRG1 or BRM loss. a–d Effect of BRG1 or BRM depletion of BRG (a, b) or BRM (c, 
d). e, f Classification of ChIP-seq peaks based on loss of BRG and BRM. g, h Quantification of gene expression changes in categories assigned in e, 
f. Asterisk denotes p value < 0.05 by Wilcoxon rank sum test against hypothesis of no change in expression. i, j Fraction of peaks in each category 
associated with significantly altered gene expression. Asterisks denote p value < 0.05 by Chi-square test relative to genes that were not associated 
with a BRG/BRM altered peak
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Fig. 6 Different regulatory classes are composed of distinct gene sets. a GSEA analysis of Group 2 genes (BRG1 loss, BRM remains) showing differ-
ent effects of shBRG1 compared to shBRM on expression in this gene signature. b Quantification of gene expression changes in the Hallmark TNF-
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Fig. 7 Distinct cofactors are associated with lost compared to retained/gained sites. a–c ChIP-seq signal for EZH2 (a) HNF4a (b) and FOXA1 (c) 
aligned to the midpoint of BRM peaks that following BRM depletion either lose (Group 3) or retain/gain (Group 4) BRG1
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differentially with BRG1 and BRM is required for eluci-
dating how a specific site is targeted by different mecha-
nisms. Our study highlights that SWI/SNF complexes are 
both biochemically and functionally heterogeneous and 
genome-wide assessments of their role in transcriptional 
regulation mediated by multiple subunits are needed to 
gain an accurate picture of their effect in a biological sys-
tem of interest.
Functional interactions control SWI/SNF occupancy 
and transcriptional output
At the occupancy level, we find primarily that BRG1 and 
BRM bind commonly throughout the genome. The level 
of BRG1 and BRM correlates well with overall transcrip-
tion. At approximately half of sites depletion of one sub-
unit leads to loss of the second subunit (70% for BRM, 
40% for BRG1), suggesting a cooperative force in binding. 
However, at a subset of sites, the sibling subunit is gained 
or may increase in occupancy.
The mechanisms of transcriptional regulation medi-
ated by mutually exclusive subunits of SWI/SNF have 
previously been grouped into two categories. In one, 
studies show that BRG1 and BRM are redundant, and 
the loss of one subunit unmasks a requirement or a new 
function for the other subunit. This principle underlies 
the observed synthetic lethality seen between BRG1 and 
BRM in multiple cancers [25, 26]. Similar mechanisms 
are believed to cause the synthetic lethality observed 
between ARID1A and ARID1B [27]. Our study provides 
evidence of this from the 1023 genes specifically affected 
following knockdown of both BRG1 and BRM (~ 20% of 
genes affected).
A second category of regulatory mechanism is antag-
onism. In this case, the two mutually exclusive subu-
nits have opposing effects on transcription. This has 
been shown in a developmental context and at specific 
genes [4, 28]. We previously observed strong antago-
nism between ARID1A and ARID1B, as well as between 
ARID1A and ARID2 at a subset of genes in HepG2 cells. 
Through double knockdown experiments at a small num-
ber of genes, we showed that the changes in expression 
observed following knockdown of ARID1A depended 
a
SWI/SNF SWI/SNF
BRG1 BRM
SWI/SNF SWI/SNF
BRG1
BRG1 Retained/Gained
Increase/Stable/Decrease Expression
EZH2
Repression
New Complex
RecruitedNew Complex
Recruited
Activation
HNF4
FOXA1
HNF4
FOXA1
c
d
b
Layer 2
Layer 1
Fig. 8 Hierarchical model of functional interactions between BRG1 and BRM. a Interactions in layer 1 are primarily between SWI/SNF complexes, 
excluding secondary complexes from the locus. Upon loss of one of the ATPase subunits, the remaining complex association with the locus, and 
transcriptional output is controlled by the identity and action of the secondary complex. Interactions with the remaining SWI/SNF complex sup-
plant SWI/SNF occupancy (b, d) or retain it c). If the remaining complex is evicted, the transcriptional output is controlled by the whether the new 
complex is repressive (b) or activating (c, d)
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on ARID1B and ARID2 [16]. Our expression and occu-
pancy data demonstrate that this mechanism is also 
found for BRG1/BRM and suggests it is generally appli-
cable to mutually exclusive subunits. We find a group of 
genes where BRG1 plays an activating role in transcrip-
tion, while BRM plays a repressive role. We observe 
another set of genes where the reverse is true, suggest-
ing that even in a single cell type there is not a consistent 
functional output to co-occupancy and co-regulation by 
BRG1 and BRM.
We observe a third class where BRG1 and BRM are 
cooperative. At these genes, loss of BRG1 was equiva-
lent to the loss of BRM and the reverse was true. The 
linkage between cooperative occupancy and cooperative 
expression regulation was not one to one. The predomi-
nant effect on occupancy appeared cooperative, even 
in instances where this did not lead to concordant gene 
expression changes.
A model linking transcription output and SWI/SNF 
occupancy
The complexity of these interactions makes defining a 
single model difficult for SWI/SNF action. We propose 
one possible model for how this occurs that involves 
hierarchical interactions between chromatin regulators 
(Fig.  8a). The first layer of the model is dependent on 
interactions between BRG1 containing SWI/SNF com-
plexes and BRM containing SWI/SNF complexes. In this 
model, BRG1 and BRM associate with their own cofac-
tors to regulate transcription. Such interactions can be 
cooperative or competitive, in both transcription and 
occupancy, depending on the specific accessory com-
plexes involved. The baseline expression of a locus under 
this condition is ‘On,’ but the precise level is controlled by 
the interaction between the two SWI/SNF complexes. If 
both SWI/SNF complexes are positive regulators, expres-
sion will be high. If the SWI/SNF complexes antagonize 
one another, the level of expression will be intermediate 
and tuned by the functional interaction between SWI/
SNF complexes.
The second layer of regulation of the locus may involve 
a second chromatin regulating complex. At baseline, 
the second complex is not sufficient to evict both SWI/
SNF complexes, and SWI/SNF regulation dominates at 
the locus. Upon loss of one of the ATPase subunits, the 
remaining subunit is also lost because a repressive com-
plex can now dominate and evict the second SWI/SNF 
complex. In a population of cells, one would expect to 
identify some enrichment for this second complex, indic-
ative of a fraction of the cell population where the sec-
ondary complex is functional.
This model is consistent with the various transcrip-
tional outputs that are observed following disruption of 
SWI/SNF occupancy. If the second layer of regulation is 
controlled by a repressive complex, such as PRC2, then 
it may evict SWI/SNF entirely, leading to both decreased 
occupancy and decreased transcription (Fig.  8b). If the 
second layer of regulation is by a positive regulator, such 
as HNF4A or FOXA1, the sibling subunit may be evicted 
if the secondary complex has its own strong chromatin 
regulator associated (Fig.  8c). This would lead to com-
plete loss of SWI/SNF, but may increase transcription. 
Alternatively, the secondary complex may be capable of 
interacting with the remaining sibling subunit. This could 
lead to retention and a transcriptional output that is 
dependent on the initial state (Fig. 8d).
The underlying mechanism that controls how a par-
ticular site is regulated remains unclear. Our analysis of 
ENCODE factors identified chromatin regulators and 
transcription factors that were specific to sites that either 
lose both subunits or retain one of the sibling subu-
nits. This suggests that at least functional interactions 
between SWI/SNF and other chromatin regulators are 
involved [29–32]. A second possibility is that post-trans-
lational modifications of SWI/SNF or associated regula-
tors control assembly and transcription at these sites. 
Few studies have looked at these modifications on SWI/
SNF; however, in breast cancer, methylation of BAF155 
by CARM1 is important for SWI/SNF activity in meta-
static progression [33]. A final possibility is that the com-
position of SWI/SNF differs between the different classes 
of sites. Future studies aimed at biochemically purifying 
subsets of SWI/SNF based on post-translational modifi-
cations or genomic loci are needed to determine which 
mechanisms above are important.
Conclusions
BRG1 and BRM have a high level of overlap in their 
localization in HepG2 cells, yet can have distinct effects 
on gene expression. In this manuscript, we used a series 
of ChIP-seq and RNA-seq experiments to investigate 
how disruption of binding of one mutually exclusive sub-
unit of a pair affected the occupancy and gene regula-
tory program controlled by the remaining complex. We 
find heterogamous interactions that can be both positive 
and negative at the gene expression and occupancy level. 
Our data suggest that this is at least partially mediated 
by site-specific cofactors at individual gene loci. We pro-
pose a model to explain these heterogeneous outputs, 
where one layer of functional interaction occurs between 
SWI/SNF remodelers, and where a second layer of regu-
lation functions above SWI/SNF. Future studies focused 
on identifying the exact biochemical compositions of 
chromatin remodelers and regulators functional at spe-
cific sites in the genome are needed to evaluate our pro-
posed model.
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Methods
Cell culture
HepG2 cells were purchased from ATCC. They were 
grown in DMEM (Gibco, Life Technologies) containing 
10% fetal calf serum supplemented with 100  units/mL 
penicillin/streptomycin (Life Technologies). Cells tested 
negative for mycoplasma contamination and were not 
passaged more than 6 times from initial cells from ATCC.
Chip‑seq
Cells were transduced with shRNA targeting BRG1 or a 
non-targeting control in the presence of 8  ug/mL poly-
brene. 2  ug/mL was added 24  h post-transfection, and 
cells were grown for a total of 7  days following trans-
duction before harvest. ChIP was performed as previ-
ously described with modifications [16]. Cells were fixed 
for 30  min at 4  C in 0.3% methanol-free formaldehyde, 
quenched for 5 min with 125 mM glycine, washed three 
times and snap-frozen in liquid nitrogen and stored at 
–  80  C. Frozen pellets were thawed for 30  min on ice, 
resuspended each pellet in 1 mL swelling buffer (25 mM 
HEPES  +  1.5  mM  MgCl2  +  10  mM KCl  +  0.1% IGE-
PAL containing 1  mM PMSF and 1X protease inhibitor 
cocktail, Roche) and incubated 10 min at 4 C. Cells were 
dounced 20 strokes with a ‘B’ pestle, and then, nuclei 
were pelleted at 2000  rpm for 7  min at 4  C. The nuclei 
were washed with 10 mL MNase digestion buffer (15 mM 
HEPES pH 7.9, 60  mM KCl, 15  mM NaCl, 0.32  M 
sucrose) and pelleted at 2000 rpm for 7 min at 4 C. The 
pellet was then resuspended in 1  mL MNase digestion 
buffer per 4e7 cells + 3.3 uL 1 M  CaCl2 per mL + PMSF 
(1 mM) and protease inhibitor cocktail (1X, Roche) and 
then incubated for 5  min at 37  C to warm. We added 
MNase (NEB M0247S 2000  U/uL) at 0.5  uL/1e7 cells 
and incubated for 15 min at 37 C with agitation. Follow-
ing digestion, the MNase was chelated using 1/50 volume 
0.5  M EGTA on ice for 5  min. We added 1 volume of 
2X IP buffer (20 mM TrisCl pH 8, 200 mM NaCl, 1 mM 
EDTA, 0.5 mM EGTA), then passed the sample for a 21G 
needle five times and added Triton X-100 to 1% final 
concentration. The sample was cleared at 13,000 RPM 
for 15  min at 4°, and chromatin [30  ug BRG1 (Abcam 
ab110641)/BRM (Cell signaling 11966)] was used incu-
bated with antibody overnight at 4°. Antibody/chromatin 
complexes were captured with protein A magnetic beads 
(Bio-Rad) for 2  h at 4° and washed 5 times with Agi-
lent RIPA (50  mM HEPES pH 7.9/500  mM LiCl/1  mM 
EDTA/1% IGEPAL-ca-630/0.7% Na-deoxycholate) 
and once with 10  mM Tris/1  mM EDTA/50  mM NaCl. 
DNA was eluted at 65  C with agitation using 100  uL 
1% SDS +  100  mM NaHCO3 made freshly. Cross-links 
were reversed overnight by adding 5 uL of 5 M NaCl and 
incubating at 65 C. DNA was treated with 3 uL RNaseA 
for 30 min at 37 C and then proteinase K for 1 h at 56 C 
and purified with Zymo Clean and Concentrator ChIP 
Kit and quantified using qubit before library preparation 
(Kapa Hyperprep).
ChIP‑seq data analysis
Mapping
Reads were aligned to hg19 using bowtie2 [34] using the 
sensitive parameters, and duplicates were removed using 
SAMtools [35]. For visualization, bigwig tracks were gen-
erated using DeepTools [36] (version 2.2.2), bamCover-
age tool with a binsize of 10 bp and extending fragments 
to the approximate nucleosome size of 150  bp. Tracks 
can be visualized using IGV [37], and bigwig files are 
available in GEO Accession number GSE102559.
Peak calling
Peaks were called using Macs2 (version 2.1.0 [38]) using 
the narrowpeak mode using the following parameters. 
Qval  =  0.01 –keep-dup-all –shift 37 –nomodel –ext-
size 147. Additionally, we filtered the peaks against the 
ENCODE blacklist regions and further recursively 
merged any peaks within 500 bp of the nearest peak. Peak 
calls for each of the six data sets are shown in Additional 
file 4.
Gain vs lost peaks
Using peak calls described above, we overlapped the 
peaks from shNS and shBRG1 or shBRM. We selected 
peaks that were lost called in shNS, but not called in on 
of the ATPase knockdown experiments to categorize 
peaks for further analysis. These were further grouped 
based on overlap of peaks in the opposite siblings experi-
ment. For example, if a BRG1 peak was lost between 
shNS and shBRG1, these BRM peak calls in these regions 
were overlapped in shNS and shBRG1 to identify BRM 
lost and BRM retained/gained peaks.
RNA‑seq
Cells were transduced with shRNA targeting BRG1, 
BRM, both combined or a non-targeting control in the 
presence of 8ug/mL polybrene. 24  h after transduction, 
2ug/mL puromycin was added and cells were maintained 
under selection until harvest (6  days). Cells were har-
vested in trizol, and RNA was extracted using the Direct-
zol RNA kit (Zymo). Libraries were prepared using the 
Kapa mRNA library kit as per manufacturer’s instruc-
tions and sequenced on a Hiseq 4000 (50 bp).
RNA‑seq data analysis
Libraries were sequenced on Hiseq  4000 (50-bp 
reads). Gene expression levels were quantitated using 
kallisto [39]. These data were converted to counts and 
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summarized per gene using tximport [40], and differen-
tial expression was carried out using DESeq2 [41] using 
an FDR of 0.05 and no explicit fold change cutoff. Raw 
count matrices used as input to DESeq2 and output of 
DESeq2 are shown in Additional files 2 and 3.
Preparation of nuclear lysates
Cells were washed with PBS and then centrifuged at 
1300  rpm for 10  min at 4  C. Cells were washed with 
20 packed cell volumes with hypotonic cell lysis buffer 
(10  mM HEPES–KOH pH 7.9, 1.5  mM  MgCl2, 10  mM 
KCl, 0.5  mM DTT plus protease inhibitors) and placed 
on ice for 10  min to swell. Cells were then centrifuged 
at 1300 rpm for 10 min at 4 C. Cells were dounced with 
B pestle in 2 packed cell volumes of hypotonic cell lysis 
buffer. Nuclei were pelleted at 1300  rpm for 10  min at 
4 C, washed with 10 packed cell volumes with hypotonic 
cell lysis buffer and centrifuged at 5000 rpm for 10 min. 
Extractions were performed twice with 0.6 volume 
nuclear lysis buffer (20  mM HEPES–KOH pH 7.9, 25% 
glycerol, 420  mM KCl, 1.5  mM  MgCl2, 0.2  mM EDTA, 
0.5  mM and protease inhibitors). Lysates were clarified 
at 14,000  rpm for 10  min at 4  C between extractions. 
Lysates were diluted with storage buffer (20 mM HEPES–
KOH pH 7.9, 20% glycerol, 0.2 mM EDTA, 0.2 mM DTT) 
to bring final KCl concentration to 150 mM and stored at 
− 80.
Immunoaffinity
Prior to beginning the IP, we washed Dynal protein A 
beads three times with PBS + 0.5% BSA at 4 C. We resus-
pended beads in 400 uL of 1X + 0.5% BSA, then added 
4–10ug of antibody and incubated overnight at 4  C. 
The following day, we thawed the nuclear lysates on ice. 
Lysates were added to antibody-conjugated beads and 
incubated overnight. Beads were washed four times with 
BC-150 (20 mM HEPES–KOH pH 7.9, 0.15 M KCL, 10% 
glycerol, 0.2 mM EDTA ph 8.0, 0.1% Tween-20, 0.5 mM 
DTT and protease inhibitors), 2  ×  BC-100 (20  mM 
HEPES–KOH pH 7.9, 0.1 M KCL, 10% glycerol, 0.2 mM 
EDTA ph 8.0, 0.1% Tween-20, 0.5  mM DTT and pro-
tease inhibitors), 1 × BC-60 (20 mM HEPES–KOH, pH 
7.9, 60 mM KCl, 10% glycerol, 0.5 mM DTT and protease 
inhibitors). Proteins were eluted from beads using 2X 
Laemmli buffer with 100 mM DTT for 10 min at 95 C.
Glycerol gradient centrifugation
Glycerol gradient centrifugation was performed as pre-
viously described [42]. Briefly, 500  ug of nuclear lysate 
was loaded onto a 10–30% glycerol gradient and cen-
trifuged at 40,000 RPM in SW-41 rotor for 16  h at 4°. 
0.5  mL fractions was collected and used for Western 
blot analysis.
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